Vaxxinity, Inc. (NASDAQ:VAXX – Get Rating)'s share price rose 15.3% on Tuesday . The company traded as high as $2.46 and last traded at $2.33. Approximately 217,932 shares were traded during mid-day trading, an increase of 82% from the average daily volume of 119,984 shares. The stock had previously closed at $2.02.

Vaxxinity Trading Up 15.3 %

The business's 50-day moving average price is $1.75 and its 200 day moving average price is $1.88. The company has a market cap of $293.71 million, a P/E ratio of -1.88 and a beta of 0.56. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.33 and a current ratio of 3.33.

Vaxxinity (NASDAQ:VAXX – Get Rating) last issued its quarterly earnings data on Thursday, November 10th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.01. As a group, analysts expect that Vaxxinity, Inc. will post -0.6 earnings per share for the current year.

Insiders Place Their Bets

Hedge Funds Weigh In On Vaxxinity

A number of large investors have recently modified their holdings of the company. Vanguard Group Inc. increased its position in Vaxxinity by 44.5% during the 3rd quarter. Vanguard Group Inc. now owns 2,212,186 shares of the company's stock valued at $4,380,000 after purchasing an additional 681,666 shares during the period. BlackRock Inc. purchased a new stake in Vaxxinity during the 3rd quarter valued at approximately $739,000. Creative Planning bought a new position in shares of Vaxxinity during the 2nd quarter valued at approximately $436,000. Renaissance Technologies LLC bought a new stake in Vaxxinity in the second quarter worth $412,000. Finally, Millennium Management LLC purchased a new stake in Vaxxinity in the second quarter worth $335,000. 20.84% of the stock is currently owned by institutional investors.

About Vaxxinity

(Get Rating)

Vaxxinity, Inc, a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and an anti-tau product candidate for various neurodegenerative conditions, including AD.

Read More

• Get a free copy of the StockNews.com research report on Vaxxinity (VAXX)
• Cathie Wood Is Buying These Stocks, Should You?
• Thor Industries Hammered Its Numbers. Is it a Buy?
• Tritium Is the Largest DC EV Charger Maker You've Never Heard Of
• United Airlines Soars Ahead of Earnings...Time to Deplane?
• Is Dividend King PPG Industries A Buy Before Earnings?

Receive News & Ratings for Vaxxinity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxxinity and related companies with MarketBeat.com's FREE daily email newsletter.